These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

508 related items for PubMed ID: 22190607

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.
    Howard A, Hoffman J, Sheth A.
    Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830
    [Abstract] [Full Text] [Related]

  • 4. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
    Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O.
    Clin Infect Dis; 2008 Jan 15; 46(2):201-11. PubMed ID: 18171251
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
    Berge M, Guillemain R, Boussaud V, Pham MH, Chevalier P, Batisse A, Amrein C, Dannaoui E, Loriot MA, Lillo-Le Louet A, Billaud EM.
    Transpl Infect Dis; 2009 Jun 15; 11(3):211-9. PubMed ID: 19302272
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Therapeutic drug monitoring of voriconazole after intravenous administration in infants and children with primary immunodeficiency.
    Gerin M, Mahlaoui N, Elie C, Lanternier F, Bougnoux ME, Blanche S, Lortholary O, Jullien V.
    Ther Drug Monit; 2011 Aug 15; 33(4):464-6. PubMed ID: 21743382
    [Abstract] [Full Text] [Related]

  • 12. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study.
    Lazarus HM, Blumer JL, Yanovich S, Schlamm H, Romero A.
    J Clin Pharmacol; 2002 Apr 15; 42(4):395-402. PubMed ID: 11936564
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Voriconazole serum concentrations in prophylactically treated acute myelogenous leukaemia patients.
    Rüping MJ, Müller C, Vehreschild JJ, Böhme A, Mousset S, Harnischmacher U, Frommolt P, Wassmer G, Drzisga I, Hallek M, Cornely OA.
    Mycoses; 2011 May 15; 54(3):230-3. PubMed ID: 19889174
    [Abstract] [Full Text] [Related]

  • 15. Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age.
    Shima H, Miharu M, Osumi T, Takahashi T, Shimada H.
    Pediatr Blood Cancer; 2010 Jul 01; 54(7):1050-2. PubMed ID: 20146339
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients.
    Michael C, Bierbach U, Frenzel K, Lange T, Basara N, Niederwieser D, Mauz-Körholz C, Preiss R.
    Antimicrob Agents Chemother; 2010 Aug 01; 54(8):3225-32. PubMed ID: 20547816
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.